Hypotensive efficacy of bimatoprost in monotherapy of primary open-angle glaucoma

Close metadata

Recommended articles:

Clinical outcomes of laser activation of hydraulic permeability of the sclera in the treatment of advanced glaucoma. Russian Annals of Ophthalmology. 2023;(6):19-25

Comparison of the effectiveness and safety of glaucoma drugs in the therapy of primary open-angle glaucoma. Russian Annals of Ophthalmology. 2023;(6):101-108

The association between myopia and glaucoma. Russian Annals of Ophthalmology. 2024;(1):93-98

Role of point-by-point light sensitivity in the assessment of glaucoma progression. Russian Annals of Ophthalmology. 2024;(2-2):34-42

Influence of corneal curvature and peripheral thickness on tonometry readings. Russian Annals of Ophthalmology. 2024;(2-2):43-50

Thresholds and variability of retinal light sensitivity in each point of the examined visual field. Russian Annals of Ophthalmology. 2024;(2-2):116-122

Factors affecting the hypotensive effect of selective laser trabeculoplasty in primary open-angle glaucoma. Russian Annals of Ophthalmology. 2024;(2):54-62

Structure of pediatric ophthalmic pathology in Uzbekistan. Russian Annals of Ophthalmology. 2024;(2):97-101

The relationship between intraocular pressure and age-related variations in ocular rigidity. Russian Annals of Ophthalmology. 2024;(3):11-18

Comparative evaluation of transscleral laser exposure in anatomical experiment. Russian Annals of Ophthalmology. 2024;(3):19-26

Purpose — to study the effectiveness of monotherapy with bimatoprost in patients with decompensated intraocular pressure (IOP). Material and methods. 90 patients (132 eyes) with stage I—II glaucoma and decompensated IOP previously treated with timolol, latanoprost and travoprost were included in the study. Average IOP at the beginning of the study was 25.4±2.5 mmHg. All patients had their hypotensive medications substituted by bimatoprost. The patients were examined during the initial appointment, as well as after 4 and 12 weeks. Results. IOP decrease was highest in the group of patients who had been treated with timolol: initially IOP was 26.2±1.8 mmHg, after 4 weeks — 21.0±2.2 mmHg, after 12 weeks — 20.8±1.9 mmHg (p<0.001). The initial IOP of patients who had been treated with latanoprost was 24.8±2.9 mmHg, 21.8±2.4 mmHg after 4 weeks, and 21.6±2.3 mmHg after 12 weeks (p<0.001). Patients who had been treated with travoprost had 25.6±2.2 mmHg initially, 23.0±2.5 mmHg after 4 weeks, and 23.2±2.6 mmHg after 12 weeks (p<0.001). By the end of the study IOP has decreased by 5.4, 3.2 and 2.4 mmHg in the groups of patients who had been treated with timolol, latanoprost and travoprost, respectively. Conclusion. Bimatoprost can be used as monotherapy if another hypotensive drug in monotherapy is insufficient for IOP compensation.

Keywords:

glaucoma

hypotensive efficacy

monotherapy

timolol

latanoprost

travoprost

bimatoprost

Authors:

Petrov S.Iu.

FGBU "NII glaznykh bolezneĭ" RAMN

Kozlova I.V.

FGBU "NII glaznykh bolezneĭ" RAMN, Moskva

Zinina V.S.

Research Institute of Eye Diseases, 11, A, B, Rossolimo St., Moscow, Russian Federation, 119021

Volzhanin A.V.

Research Institute of Eye Diseases, 11, A, B, Rossolimo St., Moscow, Russian Federation, 119021

Kravchik M.V.

Research Institute of Eye Diseases, 11A Rossolimo St., Moscow, Russian Federation, 119021

List of references:

Resnikoff S, Pascolini D, Etya’ale D, Kocur I, Pararajasegaram R, Pokha- rel GP, Mariotti SP. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004;82(11):844-851. https://doi.org/10.1590/S0042-96862004001100009
European Glaucoma Society. Terminology and guidelines for glaucoma. 4^th ed: Savona, Italy PubliComm; 2014.
Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081-2090. https://doi.org/10.1016/j.ophtha.2014.05.013
Nesterov AP, Alekseev VN, Alekseev IB, Amirov AN, Astakhov YuS, Balalin SV. Natsionalnoe rukovodstvo po glaukome dlya praktikuyuschikh vrachei. Tretye izdanie, ispr. i dop. M.: GEOTAR-Media; 2015. (In Russ.)
Leske MC, Heijl A, Hussein M., Bengtsson B., Hyman L., Komaroff E., Early Manifest Glaucoma Trial G. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol. 2003;121(1):48-56.
Prum BEJr, Rosenberg LF, Gedde SJ, Mansberger SL, Stein JD, Moroi SE, Herndon LWJr, Lim MC, Williams RD. Primary Open-Angle Glaucoma Preferred Practice Pattern((R)) Guidelines. Ophthalmology. 2016;123(1):41-111. https://doi.org/10.1016/j.ophtha.2015.10.053
Egorov EA. Hypotensive treatment of glaucoma. RMJ Klinicheskaya Oftalmologiya. 2000;1(1):6. (In Russ.)
Erichev VP. Main directions of hypotensive treatment of primary glaucoma patients. Russkiy oftalmologicheskiy zhurnal. 2000;1(1):18. (In Russ.)
Erichev VP, Dugina AE, Mazurova YuV. Fixed drug combinations: modern approach to glaucoma therapy. Glaucoma. 2010;(1):62-65. (In Russ.)
Li T, Lindsley K, Rouse B, Hong H, Shi Q, Friedman DS, Wormald R, Dickersin K. Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma: A Systematic Review and Network Meta-analysis. Ophthalmology. 2016;123(1):129-140. https://doi.org/10.1016/j.ophtha.2015.09.005
McKee HD, Gupta MS, Ahad MA, Saldana M, Innes JR. First-choice treatment preferences for primary open-angle glaucoma in the United Kingdom. Eye (Lond). 2005;19(8):923-924. https://doi.org/10.1038/sj.eye.6701674
Moore W, Nischal KK. Pharmacologic management of glaucoma in childhood. Paediatr Drugs. 2007;9(2):71-79.
Hejkal TW, Camras CB. Prostaglandin analogs in the treatment of glaucoma. Semin Ophthalmol. 1999;14(3):114-123. https://doi.org/10.153/SOPH01400114
Resul B, Stjernschantz J, No K, Liljebris C, Selen G, Astin M, Karlsson M, Bito LZ. Phenyl-substituted prostaglandins: potent and selective antiglaucoma agents. J Med Chem. 1993;36(2):243-248.
Quaranta L, Riva I, Katsanos A, Floriani I, Centofanti M, Konstas AG. Safety and efficacy of travoprost solution for the treatment of elevated intraocular pressure. Clin Ophthalmol. 2015;9:633-643. https://doi.org/10.2147/OPTH.S61444
Alexander CL, Miller SJ, Abel SR. Prostaglandin analog treatment of glaucoma and ocular hypertension. Ann Pharmacother. 2002;36(3):504-511. https://doi.org/10.1345/aph.1A178
Patil AJ, Vajaranant TS, Edward DP. Bimatoprost — a review. Expert Opin Pharmacother. 2009;10(16):2759-2768. https://doi.org/10.1517/14656560903292649
Davies SS, Ju WK, Neufeld AH, Abran D, Chemtob S, Roberts LJ, 2nd. Hydrolysis of bimatoprost (Lumigan) to its free acid by ocular tissue in vitro. J Ocul Pharmacol Ther. 2003;19(1):45-54. https://doi.org/10.1089/108076803762718105
Eisenberg DL, Toris CB, Camras CB. Bimatoprost and travoprost: a review of recent studies of two new glaucoma drugs. Surv Ophthalmol. 2002;47 (suppl 1):105-115.
Hellberg MR, Ke TL, Haggard K, Klimko PG, Dean TR., Graff G. The hydrolysis of the prostaglandin analog prodrug bimatoprost to 17-phenyl-trinor PGF2alpha by human and rabbit ocular tissue. J Ocul Pharmacol Ther. 2003;19(2):97-103. https://doi.org/10.1089/108076803321637627
Krauss AH, Woodward DF. Update on the mechanism of action of bimatoprost: a review and discussion of new evidence. Surv Ophthalmol. 2004;49(suppl 1):5-11. https://doi.org/10.1016/j.survophthal.2003.12.014
Camras CB, Toris CB, Sjoquist B, Milleson M, Thorngren JO, Hejkal TW, Patel N, Barnett EM, Smolyak R, Hasan SF, Hellman C, Meza JL, Wax MB, Stjernschantz J. Detection of the free acid of bimatoprost in aqueous humor samples from human eyes treated with bimatoprost before cataract surgery. Ophthalmology. 2004;111(12):2193-2198. https://doi.org/10.1016/j.ophtha.2004.06.028
Christiansen GA, Nau CB, McLaren JW, Johnson DH. Mechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucoma. Ophthalmology. 2004;111(9):1658-1662. https://doi.org/10.1016/j.ophtha.2004.02.006
Brubaker RF, Schoff EO, Nau CB, Carpenter SP, Chen K, Vandenburgh AM. Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics. Am J Ophthalmol. 2001;131(1):19-24.
Woodward DF, Krauss AH, Chen J, Liang Y, Li C, Protzman CE, Bogardus A, Chen R, Kedzie KM, Krauss HA, Gil DW, Kharlamb A, Wheeler LA, Babusis D, Welty D, Tang-Liu DD, Cherukury M, Andrews SW, Burk RM, Garst ME. Pharmacological characterization of a novel antiglaucoma agent, Bimatoprost (AGN 192024). J Pharmacol Exp Ther. 2003;305(2):772-785. https://doi.org/10.1124/jpet.102.047837
Brandt JD, VanDenburgh AM, Chen K, Whitcup SM., Bimatoprost Study G. Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP: a 3-month clinical trial. Ophthalmology. 2001;108(6):1023-1031; discussion 1032.
DuBiner H, Cooke D, Dirks M, Stewart WC, VanDenburgh AM, Felix C. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost. Surv Ophthalmol. 2001;45(suppl 4):353-360.
Gandolfi S, Simmons ST, Sturm R, Chen K, Vandenburgh AM, Bimatoprost Study G. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther. 2001;18(3):110-121.
Sherwood M, Brandt J, Bimatoprost Study G. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Surv Ophthalmol. 2001;45(suppl 4):361-368.
Noecker RS, Dirks MS, Choplin NT, Bernstein P, Batoosingh AL, Whitcup SM, Bimatoprost/Latanoprost Study G. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol. 2003;135(1):55-63.
Simmons ST, Dirks MS, Noecker RJ. Bimatoprost versus latanoprost in lowering intraocular pressure in glaucoma and ocular hypertension: results from parallel-group comparison trials. Adv Ther. 2004;21(4):247-262.
Dirks MS, Noecker RJ, Earl M, Roh S, Silverstein SM, Williams RD. A 3-month clinical trial comparing the IOP-lowering efficacy of bimatoprost and latanoprost in patients with normal-tension glaucoma. Adv Ther. 2006;23(3):385-394.
Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK, 2nd, Wilson MR, Gordon MO. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):701-713; discussion 829-730.
Lichter PR, Musch DC, Gillespie BW, Guire KE, Janz NK, Wren PA, Mills RP, Group CS. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001;108(11):1943-1953.
Glaucoma. Natsionalnoe rukovodstvo. Pod red. Egorova E.A. M.: GEOTAR-Media, 2013. (In Russ.)
Myers JS, Vold S, Zaman F, Williams JM, Hollander DA. Bimatoprost 0.01% or 0.03% in patients with glaucoma or ocular hypertension previously treated with latanoprost: two randomized 12-week trials. Clin Ophthalmol. 2014;8:643-652. https://doi.org/10.2147/OPTH.S59197

Close metadata